Keiko Yamamoto
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Tumor-Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development.
Journal: Clinical and translational science
Published: February 23, 2026
Retrospective Analysis of Master Protocols in Tumor-Agnostic Drug Development: Evaluation of Application to Single-Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs.
Journal: Clinical and translational science
Published: April 07, 2025
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis.
Journal: Cancer treatment reviews
Published: June 29, 2024
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Journal: Journal of gynecologic oncology
Published: September 22, 2023
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Journal: Cancer science
Published: April 04, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026